Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Treasury Shares (2016 - 2025)

Arrowhead Pharmaceuticals' Treasury Shares history spans 1 years, with the latest figure at $53.2 million for Q4 2025.

  • For Q4 2025, Treasury Shares changed N/A year-over-year to $53.2 million; the TTM value through Dec 2025 reached $53.2 million, changed N/A, while the annual FY2025 figure was $53.2 million, N/A changed from the prior year.
  • Treasury Shares reached $53.2 million in Q4 2025 per ARWR's latest filing, roughly flat from $53.2 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $5.0 million in Q2 2024 to a low of $494009.0 in Q1 2025.
  • Average Treasury Shares over 5 years is $3.3 million, with a median of $3.8 million recorded in 2021.
  • Peak YoY movement for Treasury Shares: skyrocketed 329.75% in 2024, then plummeted 82.63% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $3.6 million in 2021, then tumbled by 35.65% to $2.3 million in 2022, then crashed by 70.3% to $684900.0 in 2023, then surged by 329.75% to $2.9 million in 2024, then plummeted by 83.22% to $494009.0 in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Treasury Shares are $494009.0 (Q1 2025), $2.9 million (Q4 2024), and $5.0 million (Q2 2024).